Format
Items per page
Sort by

Send to:

Choose Destination

Results: 17

1.

In contemporary patients with polycythemia vera, rates of thrombosis and risk factors delineate a new clinical epidemiology.

Barbui T, Carobbio A, Rumi E, Finazzi G, Gisslinger H, Rodeghiero F, Randi ML, Rambaldi A, Gisslinger B, Pieri L, Bertozzi I, Casetti I, Pardanani A, Passamonti F, Vannucchi AM, Tefferi A.

Blood. 2014 Nov 6;124(19):3021-3. doi: 10.1182/blood-2014-07-591610. No abstract available.

PMID:
25377561
2.

Clinical effect of driver mutations of JAK2, CALR, or MPL in primary myelofibrosis.

Rumi E, Pietra D, Pascutto C, Guglielmelli P, Martínez-Trillos A, Casetti I, Colomer D, Pieri L, Pratcorona M, Rotunno G, Sant'Antonio E, Bellini M, Cavalloni C, Mannarelli C, Milanesi C, Boveri E, Ferretti V, Astori C, Rosti V, Cervantes F, Barosi G, Vannucchi AM, Cazzola M; Associazione Italiana per la Ricerca sul Cancro Gruppo Italiano Malattie Mieloproliferative Investigators.

Blood. 2014 Aug 14;124(7):1062-9. doi: 10.1182/blood-2014-05-578435. Epub 2014 Jul 1.

3.

Cerebral venous thrombosis and myeloproliferative neoplasms: results from two large databases.

Dentali F, Ageno W, Rumi E, Casetti I, Poli D, Scoditti U, Maffioli M, di Minno MN, Caramazza D, Pietra D, De Stefano V, Passamonti F.

Thromb Res. 2014 Jul;134(1):41-3. doi: 10.1016/j.thromres.2014.03.040. Epub 2014 Mar 29.

PMID:
24787989
4.

Abnormal expression patterns of WT1-as, MEG3 and ANRIL long non-coding RNAs in CD34+ cells from patients with primary myelofibrosis and their clinical correlations.

Pennucci V, Zini R, Norfo R, Guglielmelli P, Bianchi E, Salati S, Sacchi G, Prudente Z, Tenedini E, Ruberti S, Paoli C, Fanelli T, Mannarelli C, Tagliafico E, Ferrari S, Vannucchi AM, Manfredini R; Associazione Italiana per la Ricerca sul Cancro Gruppo Italiano Malattie Mieloproliferative (AGIMM) Investigators.

Leuk Lymphoma. 2015 Feb;56(2):492-6. doi: 10.3109/10428194.2014.910661. Epub 2014 Jun 16. No abstract available.

PMID:
24707949
5.

CALR exon 9 mutations are somatically acquired events in familial cases of essential thrombocythemia or primary myelofibrosis.

Rumi E, Harutyunyan AS, Pietra D, Milosevic JD, Casetti IC, Bellini M, Them NC, Cavalloni C, Ferretti VV, Milanesi C, Berg T, Sant'Antonio E, Boveri E, Pascutto C, Astori C, Kralovics R, Cazzola M; Associazione Italiana per la Ricerca sul Cancro Gruppo Italiano Malattie Mieloproliferative Investigators.

Blood. 2014 Apr 10;123(15):2416-9. doi: 10.1182/blood-2014-01-550434. Epub 2014 Feb 19.

6.

JAK2 or CALR mutation status defines subtypes of essential thrombocythemia with substantially different clinical course and outcomes.

Rumi E, Pietra D, Ferretti V, Klampfl T, Harutyunyan AS, Milosevic JD, Them NC, Berg T, Elena C, Casetti IC, Milanesi C, Sant'antonio E, Bellini M, Fugazza E, Renna MC, Boveri E, Astori C, Pascutto C, Kralovics R, Cazzola M; Associazione Italiana per la Ricerca sul Cancro Gruppo Italiano Malattie Mieloproliferative Investigators.

Blood. 2014 Mar 6;123(10):1544-51. doi: 10.1182/blood-2013-11-539098. Epub 2013 Dec 23.

7.

Somatic mutations of calreticulin in myeloproliferative neoplasms.

Klampfl T, Gisslinger H, Harutyunyan AS, Nivarthi H, Rumi E, Milosevic JD, Them NC, Berg T, Gisslinger B, Pietra D, Chen D, Vladimer GI, Bagienski K, Milanesi C, Casetti IC, Sant'Antonio E, Ferretti V, Elena C, Schischlik F, Cleary C, Six M, Schalling M, Schönegger A, Bock C, Malcovati L, Pascutto C, Superti-Furga G, Cazzola M, Kralovics R.

N Engl J Med. 2013 Dec 19;369(25):2379-90. doi: 10.1056/NEJMoa1311347. Epub 2013 Dec 10.

8.

A novel germline JAK2 mutation in familial myeloproliferative neoplasms.

Rumi E, Harutyunyan AS, Casetti I, Pietra D, Nivarthi H, Moriggl R, Cleary C, Bagienski K, Astori C, Bellini M, Berg T, Passamonti F, Kralovics R, Cazzola M.

Am J Hematol. 2014 Jan;89(1):117-8. doi: 10.1002/ajh.23614. No abstract available.

PMID:
24142793
9.

Survival and prognosis among 1545 patients with contemporary polycythemia vera: an international study.

Tefferi A, Rumi E, Finazzi G, Gisslinger H, Vannucchi AM, Rodeghiero F, Randi ML, Vaidya R, Cazzola M, Rambaldi A, Gisslinger B, Pieri L, Ruggeri M, Bertozzi I, Sulai NH, Casetti I, Carobbio A, Jeryczynski G, Larson DR, Müllauer L, Pardanani A, Thiele J, Passamonti F, Barbui T.

Leukemia. 2013 Sep;27(9):1874-81. doi: 10.1038/leu.2013.163. Epub 2013 Jun 6.

10.

Efficacy of ruxolitinib in chronic eosinophilic leukemia associated with a PCM1-JAK2 fusion gene.

Rumi E, Milosevic JD, Casetti I, Dambruoso I, Pietra D, Boveri E, Boni M, Bernasconi P, Passamonti F, Kralovics R, Cazzola M.

J Clin Oncol. 2013 Jun 10;31(17):e269-71. doi: 10.1200/JCO.2012.46.4370. Epub 2013 Apr 29. No abstract available.

11.

Acquired copy-neutral loss of heterozygosity of chromosome 1p as a molecular event associated with marrow fibrosis in MPL-mutated myeloproliferative neoplasms.

Rumi E, Pietra D, Guglielmelli P, Bordoni R, Casetti I, Milanesi C, Sant'Antonio E, Ferretti V, Pancrazzi A, Rotunno G, Severgnini M, Pietrelli A, Astori C, Fugazza E, Pascutto C, Boveri E, Passamonti F, De Bellis G, Vannucchi A, Cazzola M; Associazione Italiana per la Ricerca sul Cancro Gruppo Italiano Malattie Mieloproliferative.

Blood. 2013 May 23;121(21):4388-95. doi: 10.1182/blood-2013-02-486050. Epub 2013 Apr 10.

12.

Cardiovascular events and intensity of treatment in polycythemia vera.

Marchioli R, Finazzi G, Specchia G, Cacciola R, Cavazzina R, Cilloni D, De Stefano V, Elli E, Iurlo A, Latagliata R, Lunghi F, Lunghi M, Marfisi RM, Musto P, Masciulli A, Musolino C, Cascavilla N, Quarta G, Randi ML, Rapezzi D, Ruggeri M, Rumi E, Scortechini AR, Santini S, Scarano M, Siragusa S, Spadea A, Tieghi A, Angelucci E, Visani G, Vannucchi AM, Barbui T; CYTO-PV Collaborative Group.

N Engl J Med. 2013 Jan 3;368(1):22-33. doi: 10.1056/NEJMoa1208500. Epub 2012 Dec 8.

13.

COLD-PCR and innovative microarray substrates for detecting and genotyping MPL exon 10 W515 substitutions.

Brisci A, Damin F, Pietra D, Galbiati S, Boggi S, Casetti I, Rumi E, Chiari M, Cazzola M, Ferrari M, Cremonesi L.

Clin Chem. 2012 Dec;58(12):1692-702. doi: 10.1373/clinchem.2012.192708. Epub 2012 Oct 11.

14.

JAK2 GGCC haplotype in MPL mutated myeloproliferative neoplasms.

Pietra D, Casetti I, Da Vià MC, Elena C, Milanesi C, Rumi E.

Am J Hematol. 2012 Jul;87(7):746-7. doi: 10.1002/ajh.23229. Epub 2012 May 6.

PMID:
22565617
15.

Clinical relevance of murine double minute 2 single nucleotide polymorphisms 309 in familial myeloproliferative neoplasm.

Rumi E, Casetti I, Pietra D, Elena C, Ambaglio I, Pascutto C, Passamonti F, Cazzola M; AGIMM Investigators.

Am J Hematol. 2012 Jan;87(1):129-30. doi: 10.1002/ajh.22194. Epub 2011 Oct 31. No abstract available.

PMID:
22038760
16.

Identification of genomic aberrations associated with disease transformation by means of high-resolution SNP array analysis in patients with myeloproliferative neoplasm.

Rumi E, Harutyunyan A, Elena C, Pietra D, Klampfl T, Bagienski K, Berg T, Casetti I, Pascutto C, Passamonti F, Kralovics R, Cazzola M.

Am J Hematol. 2011 Dec;86(12):974-9. doi: 10.1002/ajh.22166. Epub 2011 Sep 22.

PMID:
21953568
17.

[Organ transplants in HIV infected patients. Update and recommendations].

Barcan L, Gadano A, Casetti I, Villamil F; Grupo de Consenso de Transplante de Organos Sólidos en Pacientes HIV Positivos.

Medicina (B Aires). 2011;71(1):59-65. Spanish.

PMID:
21296725
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk